| 3,164 | 17 | 104 |
| 下载次数 | 被引频次 | 阅读次数 |
2019-nCoV新型冠状病毒是引起新型冠状病毒肺炎(COVID-19)的病原。2019-nCoV为RNA病毒,属于β冠状病毒属,进化关系上更接近蝙蝠来源的SARS样冠状病毒,蝙蝠可能是其宿主。2019-nCoV在传播途径、临床特征等方面与其他引起人类严重疾病的SARS-CoV、MERS-CoV等冠状病毒具备高度的相似性,但2019-nCoV具有可供Furin蛋白酶切的位点和插入"CGGCGG"序列,导致其在传染性、变异性和适应性方面更强。2019-nCoV通过冠状病毒最外层刺突糖蛋白(S蛋白)与人体血管紧张素转化酶2蛋白的结合侵犯肺泡上皮细胞。SARS-CoV-2感染患者前期病症较轻,但后期有突然加重,甚至出现死亡,疾病的突发转变与炎症风暴相关。
Abstract:[1]HUANG C L,WANG Y M,LI X W,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.
[2]ZHOU P,YANG X L,WANG X G,et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020,579(7798):270-273.
[3]ZHU N,ZHANG D,WANG W,et al.A novel coronavirus from patients with pneumonia in china,2019[J].N Engl J Med,2020,382(8):727-733.
[4]WU F,ZHAO S,YU B,et al.A new coronavirus associated with human respiratory disease in China[J].Nature,2020,579(7798):265-269.
[5]LU R,ZHAO X,LI J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].The Lancet,2020,395(10224):565-574.
[6]李鑫,段广有,张伟,等.2019新型冠状病毒S蛋白可能存在Furin蛋白酶切位点[J].生物信息学,2020,18(2):103-108.
[7]TANG X,WU C,LI X,et al.On the origin and continuing evolution of SARS-Co V-2[J].Nat Sci Review,2020,7(6):36.
[8]GRUBAUGH N D,PETRONE M E,HOLMES E C.We shouldn’t worry when a virus mutates during disease outbreaks[J].Nat Microbiol,2020,5(4):529-530.
[9]WOO P C Y,LAU S K P,LAM C S F,et al.Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus[J].JVirol,2012,86(7):3995-4008.
[10]CUI J,LI F,SHI Z L.Origin and evolution of pathogenic coronaviruses[J].Nat Rev Microbiol,2019,17(3):181-189.
[11]闻玉梅.冠状病毒的致病性及防控[J].微生物与感染,2020,15(1):2-5.
[12]WU F,ZHAO S,YU B,et al.A new coronavirus associated with human respiratory disease in China[J].Nature,2020,579(7798):265-269.
[13]NEUMAN B W,KISS G,KUNDING A H,et al.A structural analysis of M protein in coronavirus assembly and morphology[J].J Struct Biol,2011,174(1):11-22.
[14]CARMINA V B,NIETO-TORRES J L,ALCARAZ A,et al.Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids[J].Virology,2012,432(2):485-494.
[15]CHAN J F W,HANGKOK K,ZHU Z,et al.Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J].Emerg Microbes Infect,2020,9(1):221-236.
[16]刘彬,秦照玲,戚中田.新型冠状病毒基因组结构与蛋白功能[J].微生物与感染,2020,15(1):52-57.
[17]熊子军,张喆,王雅琦,等.新型冠状病毒基因组变异与诊断[J].西安交通大学学报(医学版),2020,41(1):1-10.
[18]HOFFMANN M,KLEINE W H,SCHROEDER S,et al.SARS-Co V-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor[J].Cell,2020,181(2):271-280.
[19]LETKO M,MARZI A,MUNSTER V.Functional assessment of cell entry and receptor usage for SARS-Co V-2 and other lineage Bbetacoronaviruses[J].Nat Microbiol,2020,5(4):562-569.
[20]WRAPP D,WANG N,CORBETT K S,et al.Cryo-EM structure of the 2019-n Co V spike in the prefusion conformation[J].Science,2020,367(6483):1260-1263.
[21]CAI G,CUI X,ZHU X,et al.Hint on the COVID-19 risk:population disparities in gene expression of three receptors of SARS-Co V[J].Preprint,2020,12(24):26.
[22]ZHOU Q,YAN R,ZHANG Y,et al.Structure of dimeric fulllength human ACE2 in complex with B0AT1[J].Science,2020,367(6485):1444-1448.
[23]YAN R,ZHANG Y,GUO Y,et al.Structural basis for the recognition of SARS-Co V-2 by full-length human ACE2[J].Science,2020,367(6485):1444-1448.
[24]LI W,MOORE M J,VASILIEVA N,et al.Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J].Nature,2003,426(6965):450-454.
[25]ZHAO Y,ZHAO Z,WANG Y,et al.Single-cell RNA expression profiling of ACE2,the putative receptor of Wuhan 2019-n Cov[J].Bio Rxiv,2020.doi:https://doi.org/10.1101/2020.01.26.919985
基本信息:
DOI:
中图分类号:R373
引用信息:
[1]高光俊,穆廷杰,马娟娟,等.新型冠状病毒病原学特征与致病机制研究进展[J].山东医药,2021,61(03):111-114.
基金信息: